移动应用程序特征的偏好,以支持患有慢性心脏病的人:离散选择研究
Sumudu Avanthi Hewage1, Sameera Senanayake1,2,3, David Brain1
1Australian Centre for Health Services Innovation and Centre for Healthcare Transformation, School of Public Health and Social Work, Queensland University of Technology, 61 Musk Avenue, Brisbane, 4059, Australia, +61 07 3388 6077.
JMIR mHealth and uHealth
|April 25, 2025
概括
根据用户偏好量身定制的移动健康应用程序功能显著提高了慢性心脏病管理的采用率. 生命体征监测和个性化教育是持续参与和改善结果的关键驱动力.
科学领域:
- 数字健康数字健康
- 心血管疾病管理管理
- 医疗信息学 医疗信息学
背景情况:
- 数字健康技术为慢性疾病管理提供了解决方案,解决了获取和负担能力障碍.
- 数字健康工具的有效性取决于用户的采用和持续参与,这些受个人偏好的影响.
研究的目的:
- 量化慢性心脏病 (CHD) 患者对移动健康应用程序特定特征的偏好.
- 确定影响采用和持续使用移动健康应用程序的关键属性,以自我管理CHD.
主要方法:
- 在澳大利亚,对被诊断患有心脏病的成年人进行了一项未标记的基于网络的选择调查.
- 四个属性 (易于导航,生命体征监测,健康教育,症状日记) 通过D-最佳设计和潜在类模型分析进行了评估.
- 根据参与者的选择,估计了不同应用版本的属性重要性和采用率.
主要成果:
- 确定了两个不同的用户类别;一个类别 (85%) 倾向于应用程序的采用,特别喜欢后监测建议,定制教育和灵活的症状日记输入等功能.
- 生命体征监测成为最有影响力的属性.
- 场景分析预测基本功能采用率为84%,当应用程序功能与用户偏好保持一致时,采用率增加到92%.
结论:
- 根据用户偏好设计移动健康应用程序可以显著提高心血管疾病患者的采用和参与度.
- 推动采用的主要特点包括易于导航,生命体征监测,个性化教育和灵活的数据输入.
- 建议进行进一步的研究,以探索不同患者群体的采用因素.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:23Assessment of the Cardiovascular System I: Subjective Data
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...